Volume | 9,923,611 |
|
|||||
News | - | ||||||
Day High | 2.45 | Low High |
|||||
Day Low | 1.75 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.34 | 1.75 | 2.45 | 3.32 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
59,810 | 9,923,611 | US$ 2.00 | US$ 19,859,453 | - | 1.75 - 140.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
13:55:31 | 50 | US$ 1.8307 | USD |
Sunshine Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
46.22M | 25.68M | - | 24.09M | -4.51M | -0.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sunshine Biopharma News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 8.50 | 8.50 | 1.75 | 6.62 | 16,078,533 | -6.67 | -78.47% |
1 Month | 6.00 | 13.25 | 1.75 | 9.50 | 28,803,667 | -4.17 | -69.50% |
3 Months | 25.50 | 28.56 | 1.75 | 8.39 | 25,680,786 | -23.67 | -92.82% |
6 Months | 30.01 | 32.98 | 1.75 | 8.51 | 11,996,930 | -28.18 | -93.90% |
1 Year | 69.00 | 140.00 | 1.75 | 12.88 | 6,336,911 | -67.17 | -97.35% |
3 Years | 275.00 | 987.00 | 1.75 | 176.89 | 4,477,459 | -273.17 | -99.33% |
5 Years | 275.00 | 987.00 | 1.75 | 176.89 | 4,477,459 | -273.17 | -99.33% |
Sunshine Biopharma Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |